Adaptimmune Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:473A Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
17 Jan 24	Sell€14,635	John Lunger	Individual	22,795	€0.73
17 Jan 24	Sell€15,127	William Bertrand	Individual	23,589	€0.73
17 Jan 24	Sell€25,417	Adrian G. Rawcliffe	Individual	39,384	€0.73
17 Jan 24	Sell€12,993	Elliot Norry	Individual	20,563	€0.73
12 Jan 24	Sell€7,124	John Lunger	Individual	9,229	€0.78
12 Jan 24	Sell€22,552	Adrian G. Rawcliffe	Individual	29,202	€0.78
12 Jan 24	Sell€9,132	Elliot Norry	Individual	11,808	€0.78
12 Jan 24	Sell€7,124	William Bertrand	Individual	9,229	€0.78
01 Sep 23	Sell€1,736	Adrian G. Rawcliffe	Individual	2,403	€0.72
01 Aug 23	Sell€2,557	John Lunger	Individual	3,096	€0.83
10 Jul 23	Sell€39,558	Garry Menzel	Individual	47,702	€0.83
27 Jun 23	Sell€1,959	Adrian G. Rawcliffe	Individual	2,333	€0.84

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 473A?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	10,664	0.00417%
Individual Insiders	1,753,808	0.686%
VC/PE Firms	17,079,778	6.68%
Hedge Funds	66,378,255	26%
General Public	82,310,031	32.2%
Institutions	88,029,443	34.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.2%.

Top Shareholders

Top 25 shareholders own 66.18% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
15.3%	Matrix Capital Management Company, LP	38,974,185	€41.7m	0%	0.39%
10.7%	EcoR1 Capital, LLC	27,404,070	€29.3m	0%	0.96%
6.68%	New Enterprise Associates, Inc.	17,079,778	€18.3m	0%	1.11%
6.23%	Baillie Gifford & Co.	15,912,140	€17.0m	0%	0.01%
4.73%	Long Focus Capital Management LLC	12,086,915	€12.9m	10.3%	1.73%
4.29%	Baker Bros. Advisors LP	10,969,282	€11.7m	0%	0.15%
4.08%	PFM Health Sciences, LP	10,423,135	€11.1m	0%	0.76%
2.17%	MPM Asset Management, L.L.C.	5,555,461	€5.9m	-11.6%	2.55%
1.99%	BioImpact Capital LLC	5,095,912	€5.4m	0%	1.09%
1.84%	Bank of America Corporation, Asset Management Arm	4,696,954	€5.0m	0.02%	no data
1.72%	Tang Capital Management, LLC	4,387,238	€4.7m	-15.1%	0.53%
1.33%	Citadel Advisors LLC	3,399,514	€3.6m	-4.23%	no data
0.95%	Rock Springs Capital Management LP	2,425,468	€2.6m	-13%	0.08%
0.77%	Morgan Stanley, Investment Banking and Brokerage Investments	1,956,373	€2.1m	-4.42%	no data
0.62%	Impresa Management LLC	1,578,783	€1.7m	0%	0.73%
0.54%	Syncona Investment Management Limited	1,377,294	€1.5m	0%	0.47%
0.54%	Renaissance Technologies LLC	1,370,239	€1.5m	33.3%	no data
0.36%	JP Morgan Asset Management	928,224	€992.4k	0%	no data
0.28%	Redmile Group, LLC	715,607	€765.1k	0%	0.03%
0.27%	Garry Menzel	686,295	€733.7k	0%	no data
0.19%	Acuitas Investments, LLC	479,789	€513.0k	0.01%	0.21%
0.17%	Millennium Management LLC	441,032	€471.5k	47%	no data
0.17%	Rathbones Investment Management Limited	432,818	€462.8k	0%	no data
0.15%	U.S. Global Investors, Inc.	382,553	€409.0k	0%	0.03%
0.14%	GSA Capital Partners LLP	370,179	€395.8k	-27.3%	0.04%